Abstract
BACKGROUND: The aim of this work was to investigate the short- and long-term test-retest reliability of the 6-min walk distance (6MWD), peak heart rate, and nadir oxygen desaturation in idiopathic pulmonary fibrosis (IPF).
METHODS: A reliability study of 70 adults with IPF was undertaken within out-patient pulmonary rehabilitation programs at 2 tertiary hospitals. Participants completed 2 baseline 6-min walk tests using a standard protocol, with continuous measures of percutaneous SpO2 and heart rate via pulse oximetry. The 6-min walk test was completed immediately following an intervention period and 6 months after. Reproducibility was assessed by intraclass correlation coefficient and Bland-Altman analysis.
RESULTS: Participants with a mean ± SD diffusing capacity of the lung for carbon monoxide of 48 ± 14% were included. The reliability of the 6MWD was high (intraclass correlation coefficient = 0.96) with a mean learning effect of 21 m (95% CI 12–30 m). The learning effect persisted at 8 weeks (mean 14 m, 95% CI 5–23 m) but not 6 months (mean 15 m, 95% CI −1 to 30 m). Using the best (greatest) 6MWD significantly reduced the proportion of participants who were classified as having a clinically important response to rehabilitation compared with using the first 6MWD (40% vs 54%, P = .002). Nadir SpO2 was reproducible, with a mean difference of 0.7 ± 2.2%, and limits of agreement of −4 to 5%. Peak heart rate was more variable, with mean difference 5 ± 9 beats/min and limits of agreement of −12 to 20 beats/min.
CONCLUSIONS: The 6MWD is a reproducible measure of exercise capacity in people with IPF. Whereas the nadir SpO2 may be accurately determined from one test, evaluating change in 6MWD with interventions may require 2 tests on each occasion. (ClinicalTrials.gov registration NCT0016828.)
Footnotes
- Correspondence: Anne Holland PhD, La Trobe University Clinical School, Level 4, The Alfred Centre, 99 Commercial Road, Melbourne 3004, Australia. E-mail: A.Holland{at}alfred.org.au.
This work was supported by the Pulmonary Fibrosis Foundation and American Thoracic Society Foundation. The authors have disclosed no conflicts of interest.
Dr Holland presented part of this work at the American Thoracic Society Annual Scientific Meeting, held May 17-22, 2013, in Philadelphia, Pennsylvania.
- Copyright © 2018 by Daedalus Enterprises